Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHair thinning affects some people taking Wegovy (semaglutide), and it appears in the official side-effect data. Clinical trials reported it in roughly 3% of participants at the 2.4mg maintenance dose, compared with around 1% on placebo. The condition behind it isn't the medicine itself damaging hair follicles — it's the body's response to rapid weight loss, a well-documented phenomenon called telogen effluvium. Wegovy is a prescription-only medicine; a GPhC-registered prescriber assesses suitability before any treatment begins, and hair concerns are exactly the kind of thing worth raising at that point.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is one of the most Googled questions among people starting semaglutide, and it deserves a straight answer: yes, hair thinning is listed as a recognised side effect in the Wegovy SmPC, and it showed up in the STEP trials. But the mechanism matters. Semaglutide doesn't attack your follicles. What it does, very effectively, is reduce appetite and body weight, sometimes quickly. The body treats significant or fast weight loss as a physiological stressor, responding by pushing a larger-than-usual proportion of hairs into the resting (telogen) phase simultaneously. When those hairs shed two to four months later, it can look alarming.
The NHS medicines page for semaglutide lists hair loss under uncommon side effects (affecting up to 1 in 100 people in some analyses; the STEP trial figure of ~3% sits at the higher end of estimates depending on how loss was measured). Either way, most people on Wegovy won't experience noticeable thinning. For those who do, our page on whether Wegovy can make you lose your hair explains why understanding the cause tends to reduce anxiety considerably, because telogen effluvium is almost always temporary.
Our full semaglutide guide covers how the medicine works and what to expect across the treatment course.
Telogen effluvium has a characteristic timing. Because hairs spend two to four months in the resting phase before falling, the peak shed usually hits around three to six months after the weight-loss trigger, which, in this context, often means three to six months after starting Wegovy or after a significant dose step-up. People sometimes describe noticing more hair in the shower or on a hairbrush rather than visible thinning patches; diffuse loss across the scalp is more typical than bald spots.
Reassuringly, the process generally self-limits. As body weight stabilises and the acute calorie deficit eases, the follicle cycle normalises. Most people who experience this find the shedding slows within six to nine months without any change to their treatment. Stopping Wegovy is rarely the right response to hair thinning alone, and doing so should only happen after talking with your prescriber about the balance of benefits and side effects for your specific situation.
If you're researching what others on semaglutide report, our page on losing hair on Wegovy looks at the pattern in more detail.
The shedding pattern isn't unique to the injectable form of semaglutide. Telogen effluvium follows significant calorie restriction or rapid weight change broadly, so anyone losing weight quickly, by any means, faces some risk of temporary thinning. The STEP trial data that reported ~3% hair loss was collected on the 2.4mg weekly injection. Hair thinning as a side effect of semaglutide in other formulations follows logically from the same mechanism, though trial data for the recently approved oral form (Wegovy tablets) is still limited.
People sometimes ask whether semaglutide causes hair loss differently from tirzepatide (Mounjaro). Both medicines produce significant weight reduction and both appear in hair-related discussions for the same reason. The SURMOUNT-1 trial data for tirzepatide similarly listed alopecia as an uncommon finding. This isn't a semaglutide-specific quirk; it reflects what happens when the body loses weight at speed. Our page on whether semaglutide makes you lose hair addresses that specific angle if you want to go deeper.
For a broader look at the Wegovy treatment itself, including eligibility and what treatment involves, see our Wegovy overview.
There's no single proven remedy, but several practical steps are well-supported by the underlying biology. Protein is the place to start: hair is largely keratin, and a significant calorie deficit that's also low in protein gives the body a ready reason to deprioritise follicle cycling. Aiming for adequate daily protein (your prescriber or a dietitian can advise on a target that suits your weight and activity level) is one of the clearest levers you have.
Iron, zinc, biotin and B vitamins are also implicated in hair growth; deficiency of any of them is more likely during active weight loss. A blood test to check ferritin and B12 levels before or early in treatment is worth discussing with your prescriber or GP, particularly if you already know you tend to run low. Standard multivitamins may help fill gaps, though they're not a replacement for adequate dietary intake. Crash eating or very-low-calorie periods make the situation worse, not better.
Practically, gentle handling matters too: heat styling, tight hairstyles and harsh brushing all increase mechanical loss when hair is already cycling more rapidly. None of this requires stopping treatment. If the thinning is severe or doesn't resolve, a GP or dermatologist can rule out other causes (thyroid dysfunction, for instance, shares some of the symptom pattern).
Wegovy is a prescription-only medicine, so all of this sits within a clinical conversation. If you're curious about what treatment through a regulated UK pharmacy looks like, our Wegovy cost context page explains what private pricing typically covers. The clinical team at nume reviews every consultation personally, it's a good place to raise concerns like this one before you start.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.